Tranexamic acid

Tranexamic acid, a synthetic derivative of the amino acid lysine, is a potent antifibrinolytic medication. Its primary function is to inhibit the activation of plasminogen to plasmin, effectively stalling the process of fibrinolysis. In comparison to similar agents like aminocaproic acid, tranexamic acid stands out for its longer half-life, increased potency, and reduced toxicity.

Tranexam

Mechanism of Action

The key to tranexamic acid's function is its high affinity for the five lysine-binding sites of plasminogen. By competitively binding to these sites, tranexamic acid inhibits the conversion of plasminogen to plasmin. Plasmin is an enzyme that is instrumental in the breakdown of fibrin, a protein that forms a mesh-like structure to hold blood clots together. Therefore, by inhibiting plasmin formation, tranexamic acid effectively hinders the process of fibrinolysis, or clot breakdown. At higher concentrations, it can also inhibit plasmin noncompetitively.

Clinical Applications

Tranexamic acid is used widely in the management of bleeding conditions. This includes use in surgeries, trauma, heavy menstruation, and bleeding disorders such as hemophilia. It's also used to prevent and treat bleeding in people with blood clotting disorders and those who have had brain surgery.

Safety and Side Effects

Tranexamic acid is generally considered safe but, as with all medications, can present side effects. Common side effects may include nausea, vomiting, diarrhea, and mild visual disturbances. Rare but serious side effects can include blood clots, stroke, and impaired color vision.

Pharmacokinetics

The advantage of tranexamic acid over similar drugs like aminocaproic acid is its superior pharmacokinetic profile. It has a longer half-life, allowing for less frequent dosing, and it is approximately ten times more potent.

References

• Mechanism of action of tranexamic acid
• Clinical applications of tranexamic acid
• Pharmacokinetics and safety profile of tranexamic acid

Tranexamic acid Resources
Latest articles Most recent articles Ongoing trials	Wikipedia